GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaCyte Biotech Inc (NAS:PMCB) » Definitions » YoY EPS Growth

PharmaCyte Biotech (PharmaCyte Biotech) YoY EPS Growth : -1,525.00% (As of Jan. 2024)


View and export this data going back to 2003. Start your Free Trial

What is PharmaCyte Biotech YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. PharmaCyte Biotech's YoY EPS Growth for the quarter that ended in Jan. 2024 was -1,525.00%.

PharmaCyte Biotech's Earnings per Share (Diluted) for the three months ended in Jan. 2024 was $-0.65.

PharmaCyte Biotech YoY EPS Growth Historical Data

The historical data trend for PharmaCyte Biotech's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaCyte Biotech YoY EPS Growth Chart

PharmaCyte Biotech Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 63.03 23.71 42.07 88.98 18.52

PharmaCyte Biotech Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 83.33 -300.00 -188.89 -1,525.00

PharmaCyte Biotech YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

PharmaCyte Biotech's YoY EPS Growth for the fiscal year that ended in Apr. 2023 is calculated as:

YoY EPS Growth (A: Apr. 2023 )
=(Earnings per Share (Diluted) (A: Apr. 2023 )-Earnings per Share (Diluted) (A: Apr. 2022 ))/ | Earnings per Share (Diluted) (A: Apr. 2022 ) |
=(-0.22--0.27)/ | -0.27 |
=18.52 %

PharmaCyte Biotech's YoY EPS Growth for the quarter that ended in Jan. 2024 is calculated as:

YoY EPS Growth (Q: Jan. 2024 )
=(Earnings per Share (Diluted) (Q: Jan. 2024 )-Earnings per Share (Diluted) (Q: Jan. 2023 )) / | Earnings per Share (Diluted) (Q: Jan. 2023 )) |
=(-0.65--0.04)/ | -0.04 |
=-1,525.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of PharmaCyte Biotech's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmaCyte Biotech (PharmaCyte Biotech) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaCyte Biotech Inc (NAS:PMCB) » Definitions » YoY EPS Growth
Comparable Companies
BNTC KALA INDP AAGH ORGS NERV NBIO OTLC GLTO AVTX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
Website
https://www.pharmacyte.com
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes will be developed. It is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
Executives
Wayne Remell Walker director 1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103
Robert Weinstein director 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Jack E Stover director C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Daniel Stuart Farb director 100 ESSEX RD., CHESTNUT HILL MA 02467
Jonathan Schechter director C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
Daniel Allen director 299 PARK AVENUE SOUTH, SUITE 90959, NEW YORK NY 10003
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Matthias Loehr director 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Yuen Thomas C K director
Carlos Trujillo director, officer: CFO 8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Kenneth L. Waggoner director, officer: Chairman, CEO, Pres and GC 8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Gerald W Crabtree director, officer: Chief Science Officer 12510 PROSPERITY DR., SUITE #310, SILVER SPRING MD 20904
Thomas Liquard director C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 92653
Raymond Cf Tong director C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099
Michael M Abecassis director C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099